GANX
Gain Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$78.60M
P/E Ratio
—
EPS
$-0.61
Beta
0.11
52W High
$4.34
52W Low
$1.41
50-Day MA
$2.13
200-Day MA
$2.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. The company is headquartered in Bethesda, Maryland.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-10.07M |
| EBITDA | $-18.69M |
| Operating Margin | 0.00% |
| Return on Equity | -155.70% |
| Return on Assets | -67.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.44 |
| Price-to-Book | 4.26 |
| Price-to-Sales (TTM) | 255.50 |
| EV/Revenue | 138.33 |
| EV/EBITDA | -1.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $42.49M |
| Float | $40.90M |
| % Insiders | 3.09% |
| % Institutions | 19.12% |
Analyst Ratings
Consensus ($7.60 target)
1
Strong Buy4
BuyData last updated: 4/8/2026